Division of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA.
Division of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA.
HPB (Oxford). 2021 Aug;23(8):1277-1284. doi: 10.1016/j.hpb.2021.01.002. Epub 2021 Jan 18.
Concurrent resection of the primary cancer and synchronous colorectal cancer liver metastases (CRCLM) was evaluated for differences in outcomes following stratification of both the liver and colorectal resection.
Consecutive cases of synchronous resection of both the CRC primary and CRCLM were reviewed retrospectively at a single, high-volume institution over a 17-year period (2000-2017).
273 patients underwent simultaneous resection of CRCLM. The distribution of the primary lesion was similar between the colon (52.4%) and rectum (47.6%), while 46.9% of patients had bilobar liver disease. Major liver/major colorectal resection (n = 24) were significantly more likely to experience colorectal specific morbidity (OR 3.98, 95% CI 1.56-10.15, p = 0.004), liver specific morbidity (OR 7.4, 95% CI 2.22-24.71, p = 0.001), total morbidity (OR 2.91, 95% CI 1.18-7.18, p = 0.020) and 90-day mortality (OR 5.50, 95% CI 1.27-23.81, p = 0.023). Failure to receive adjuvant chemotherapy secondary to postoperative morbidity was associated with significantly worsened survival (HR for death 5.91, 95% CI 1.59-22.01, p = 0.008).
Postoperative morbidity precluding the administration of adjuvant chemotherapy is associated with an increase in mortality. Combining a major liver with major colorectal resection is associated with a significant increase in major morbidity and 90-day mortality, and should be avoided.
对原发性癌症和结直肠癌肝转移(CRCLM)同时切除的患者进行分层,比较肝切除术和结直肠切除术的结果。
回顾性分析了一家高容量机构在 17 年内(2000 年至 2017 年)连续接受同步切除结直肠原发灶和 CRCLM 的患者。
273 例患者同时接受了 CRCLM 切除。结肠(52.4%)和直肠(47.6%)原发肿瘤的分布相似,而 46.9%的患者有双侧肝疾病。主要肝/主要结直肠切除术(n=24)更可能发生结直肠特异性发病率(OR 3.98,95%CI 1.56-10.15,p=0.004)、肝特异性发病率(OR 7.4,95%CI 2.22-24.71,p=0.001)、总发病率(OR 2.91,95%CI 1.18-7.18,p=0.020)和 90 天死亡率(OR 5.50,95%CI 1.27-23.81,p=0.023)。术后并发症导致无法接受辅助化疗与生存率显著下降相关(死亡风险 HR 为 5.91,95%CI 1.59-22.01,p=0.008)。
术后并发症导致无法接受辅助化疗与死亡率增加相关。联合主要肝切除术和主要结直肠切除术与严重发病率和 90 天死亡率显著增加相关,应予以避免。